The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145
However, the availability of refurbished products, the lack of skilled professionals, and product recalls are expected to hamper the market growth to a certain extent in the coming years.
The global anatomic pathology market for instruments and consumables is consolidated. The top five companies in this market are F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Beckton, Dickson and Company (US), and Abcam plc. (UK).
- Hoffmann-La Roche AG (Switzerland) is the leading player in the anatomic pathology market in 2020. The company has a wide range of products in the consumables segment. Strong business operations across all key regions, coupled with a strong brand image, make the firm a leading player in this market. F. Hoffman-La Roche has adopted organic business strategies such as product launches in order to maintain its leading position in the anatomic pathology market. For instance, in 2020, the company received FDA approval for its CINtec PLUS Cytology test. Similarly, in 2018, the company received CE approval for its BenchMark ULTRA Plus staining system.
Danaher Corporation (US) is the second-leading player in the anatomic pathology market in 2020. The company has a broad product portfolio in the instruments segment. Moreover, Danaher also has a strong geographic presence with its direct distribution channels across the globe. The impressive product portfolio of the firm is complemented by its client support services. Over the years, Danaher has maintained its leading position in the market through continuous innovation and the launch of advanced products. For example, in 2018, Danaher launched various clinical microtomes, such as the HistoCore BIOCUT, HistoCore MULTICUT, and HistoCoreAUTOCUT clinical microtomes.
Request for Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062